🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Genfleet Therapeutics (Shanghai) clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Genfleet Therapeutics (Shanghai) as lead sponsor. Synced 26 Sep 2026
11Current trials
7Recruiting now
12Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Genfleet Therapeutics (Shanghai) is the lead sponsor of 11 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Cetuximab, GFH276 and GFH009. The most-studied condition is PDAC.

ClinicalTrials.gov trials by status

  • Recruiting764%
  • Not yet open436%

Trials by phase

  • Phase 1/2655%
  • Phase 3218%
  • Phase 2218%
  • Phase 119%
01

Clinical trials sponsored by Genfleet Therapeutics (Shanghai)

11 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
NCT06375733 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma
Phase 1/2 Recruiting 2024-03 China
A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia
NCT06898255 · ClinicalTrials.gov ↗ · Cancer Cachexia
Drug: GFS202A
Phase 1 Recruiting 2025-04 China
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
NCT07668752 · ClinicalTrials.gov ↗ · KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)
Phase 3 Recruiting 2026-07 China
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
NCT07262567 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer
Drug: Cetuximab
Phase 3 Recruiting 2025-12 China
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676 · ClinicalTrials.gov ↗ · KRAS G12D Mutations, Advanced Solid Tumors
Drug: Cetuximab
Phase 1/2 Recruiting 2024-07 China
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT05934513 · ClinicalTrials.gov ↗ · Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Drug: GFH009
Phase 1/2 Recruiting 2023-09 China
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
NCT07259590 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
Phase 1/2 Recruiting 2025-10 China
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
NCT07198321 · ClinicalTrials.gov ↗ · Cancer, PDAC, CRC (Colorectal Cancer)
Drug: GFH276
Phase 1/2 Not yet open 2025-09 China
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
NCT07784374 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Phase 2 Not yet open 2026-08 China
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
NCT07678593 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Phase 1/2 Not yet open 2026-09 China
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
NCT07554859 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)
Drug: Cetuximab
Phase 2 Not yet open 2026-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Genfleet Therapeutics (Shanghai) trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Genfleet Therapeutics (Shanghai) trials

17 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China117

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in PDAC

SponsorTrials
Revolution Medicines6
Immuneering Corporation1
Tango Therapeutics1
InxMed (Shanghai)1

Sponsors with the most current trials registered for this condition.

06

Questions about Genfleet Therapeutics (Shanghai) trials

How many clinical trials does Genfleet Therapeutics (Shanghai) sponsor?

Genfleet Therapeutics (Shanghai) is the lead sponsor of 11 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Genfleet Therapeutics (Shanghai) trials recruiting?

Yes. 7 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Genfleet Therapeutics (Shanghai) testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are Cetuximab (6), GFH276 (3), GFH009 (2), GFS202A (2) and Docetaxel (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.